Through its subsidiary of PT Global Onkolab Farma (GOF), PT Kalbe Farma Tbk (Kalbe) officially inaugurates a radioisotope factory that especially produces Fluorodeoxyglucose (FGD) for the early detection of cancer. This inauguration was attended by the Ministry of Health of the Republic of Indonesia, Budi Gunadi Sadikin, the Head of the Food and Drug Supervisory Authority (BPOM), Taruna Ikrar, representatives of the Nuclear Energy Regulatory Agency of Indonesia (BAPETEN), and the President Director of PT Kalbe Farma Tbk, Irawati Setiady.
“The building of this domestic radioisotope factory is a form of Kalbe’s commitment to continuously improve access to affordable healthcare for the people, especially in cancer detection,” says the President Director of PT Kalbe Farma Tbk, Irawati Setiady.
Irawati adds that the building of this radioisotope factory is in line with the Law No.17 Year 2023 on the six Pillars of Health Transformation with emphasis on the sixth pillar, the Transformation of Health Technology. “This domestic-produced radioisotope is the company’s contribution towards national health independence and improved health for a better life,” Irawati says.
Irawati continues that the Fluorodeoxyglucose (FGD)-producing radioisotope factory is vital to support Positron Emission Tomography and Computed Tomography Scanning (PET/CT-Scan) exam services in hospitals. She hopes that Kalbe’s radioisotope production can help fulfill the needs of hospitals in PET/CT-Scan while helping to improve access for more cancer patients that they could get comprehensive cancer therapies.
Today, there is a limited number of radiofarmaka production facilities domestically, while the needs for them go higher. This in turn creates long waiting times for PET-Scan diagnoses and services for patients, which causes them to travel overseas for the sole purpose of being examined.
Kalbe fully supports the government’s transformation efforts by building radioisotope and radiofarmaka production facilities. The building, which began with the groundbreaking procession on the 1st of February, 2024, has been run with full force by maintaining focus on all licensing aspects and occupational health and safety aspects (K3/Keselamatan & Kesehatan Kerja). Therefore, in parallel with the building process of the radioisotope and radiofarmaka facilities, Kalbe communicates and collaborates with various parties from regulators (the Ministry of Health, BAPETEN, BPOM), hospitals, professional organizations, and academic civitates.
A PET/CT-Scan is an advanced medical imagery examination that gives detailed information on the functions of organs or systems of the body. This examination is especially used to detect the presence of cancer. Compared to MRI or CT scans, a PET-Scan or a PET-MRI Scan could give more information to help in determining a cancer’s stage.
Global Onkolab Farma at a Glance
PT Global Onkolab Farma is one of the subsidiaries of PT Kalbe Farma that focuses on the development and creation of various kinds of cancer medicines, including prescription-based drugs, therapies, and supporting regimens.
Operating in Indonesia, this company is one of the first cancer drugs manufacturers that specialize in local manufacturing of high-quality affordable oncology products by utilizing advanced technology.
To serve cancer patients better, PT Global Onkolab Farma is committed in developing more effective cancer drugs and other cancer-related services, such as nutritional products and by collaborating with nearby cancer communities to provide support systems for cancer patients.
Kalbe at a Glance
PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a portfolio of dependable and various brands: the prescription pharmaceutical division, the health products division that handles over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks, the nutritions division, and the distribution & logistics division.
Kalbe has also developed B2B-based digital services ecosystems for the society: EMOS and MOSTRANS. EMOS is an order management application system that helps distribution channels perform their stock or supply chain management actions. MOSTRANS is a B2B transportation solution provider for the easy management and the efficiency of transportation.
Kalbe now has more than 49 subsidiaries and 14 international-standard production facilities, supported by around 16,000 employees in 71 branches throughout Indonesia. Kalbe’s shares have been listed in Indonesia Stock Exchange/Bursa Efek Indonesia (IDX:KLBF) since 1991. For more information, please visit https://www.kalbe.co.id/